Vilon
Vilon is a dipeptide (Lys-Glu) from the Khavinson bioregulator line, researched for immune system modulation and cellular longevity. Community protocols are thinly documented — no modal dose, timing, or cycling pattern has emerged in TVR's tracked sources, and real-world use data for this peptide remains sparse. All human use is off-label and compounded, with no regulatory approval in any jurisdiction; the evidence base here sits well below that of more extensively studied peptides on this site.
Research Evidence
Evidence shape
No completed human trials extracted for Vilon. Animal-model evidence carries the indication cards below.
Anecdotal efficacy
Side effects
Clinical research side effects
Clinical safety table not projected yet.
Anecdotal side effects
Price
price offers can be sorted by column
Dosing & Protocol
How Vilon is dosed across research, clinician, and community sources — each evidence tier kept separate so the dose range, frequency, timing, and cycling stay visible without flattening different levels of evidence.
- Frequency
- unspecified
- Timing
- unspecified
- Route
- subQ
- Cycle
- unspecified
Current clinical research data for Vilon (Lys-Glu) is limited to preclinical/mechanistic animal studies, with no specific human trial dosing protocols available.
No structured protocol details captured for this tier yet.
No structured protocol details captured for this tier yet.
Peptide Deep Dive
Peptide Deep Dive is not projected for this peptide yet.
Peptide feedback
0 forum repliesLive community discussion for Vilon, shown here in the site layout and continued on the TVR forum.
No peptide feedback yet
Start the peptide feedback thread on the TVR forum.